Home > News > Optical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration
Read Time: 10 mins

Optical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration

Published Online: March 27th 2012 European Ophthalmic Review, 2012;[ePub ahead of print]
Authors: Albert J Augustin
Quick Links:
Article Information

The purpose of this article is to show the feasibility of the ‘Advanced [retinal pigment epithelium] RPE analysis’ software tool to measure drusen area and volume as well as the area of geographic atrophy (GA) in patients with dry age-related macular degeneration (AMD). The source data from spectral domain optical coherence tomography (SD-OCT) images obtained from three patients with confirmed dry AMD using Cirrus™ HD-OCT (Carl Zeiss Meditec) were re-evaluated with the new software analysis tool Advanced RPE analysis. The area of GA as well as drusen area and volume were measured and analysis of results were presented along with calculated values in two clearly arranged screens. Changes between visits were easily detectable and could be followed over time. Results correlated well with clinical observation. The conclusion reached was that the new Advanced RPE analysis software allows the automated, objective and quantitative assessment of atrophic lesions and drusen. It thus could prove to be useful in determining disease stages as well as prognosis more precisely, and provides the opportunity to monitor the effectiveness of new therapies in clinical trials.


Spectral domain optical coherence tomography (SD-OCT), imaging, drusen, geographic atrophy, age-related macular degeneration (AMD), dry AMD, Advanced retinal pigment epithelium (RPE) analysis tool


Age-related macular degeneration (AMD) is the leading cause of blindness among elderly individuals in developed industrialised countries and affects approximately 30–50 million people worldwide.1–4 There are two forms of AMD: dry AMD (dAMD) which accounts for about 80 % of all cases of AMD, and neovascular AMD (nAMD). Early stage AMD is characterised by soft drusen (protein and lipid deposits between retinal pigment epithelium [RPE] and Bruch’s membrane) and pigment abnormalities (hyper- or hypopigmentation). Visual acuity is usually not deteriorated in early stages of AMD. However, they can progress to late stages of AMD: geographic atrophy (GA; late stage of dAMD) or neovascular AMD. Vision loss due to AMD is mainly attributable to these advanced forms. It is estimated that due to demographic changes, in 2020 the vision-threatening advanced forms will increase by more than 50 %.5 Thus, a better understanding of the pathogenesis may lead to the development of new powerful therapies and is a matter of public and economic concern.

While there are several therapeutic approaches for nAMD, so far there are no established guidelines for dry AMD treatment. Although vitamin supplementation can slow the progression of dAMD in advanced forms, uncritical administration is not advisable due to possible adverse reactions.6,7 New drugs and advanced concepts for the treatment of dry AMD are waiting for further investigation.8–11 However, their evaluation of efficacy against dry AMD turns out to be difficult and time consuming. In contrast to nAMD, patients with dry AMD can maintain good central visual acuity until the disease progresses into the foveal centre. Thus, visual acuity might not be an appropriate clinical end-point in early stage clinical trials to determine drug efficacy against dry AMD. Therefore, new reliable clinical trial end-points enabling efficacy evaluation in the shortest period of time are needed. Furthermore, diagnostic methods should be established which allow for reliable, objective, automated and quantitative assessment of disease progression in large patient populations.

As eyes with soft indistinct drusen or retinal pigmentary abnormalities at baseline are more likely to develop late AMD as compared to eyes without these lesions,12 two encouraging options to monitor progression of dry AMD are the volumetric assessment of drusen as well as localisation and quantitative assessment of atrophic lesions in GA.

The gold standard for assessing drusen number and size as well as pigmentary changes are stereoscopic colour fundus photographs analysed by qualified reading centres.13,14 Fundus autofluorescence (FAF) has also been used for imaging of atrophic lesions in GA to indicate GA progression.15–17 However, accuracy delineating GA by fundus photography has been reported to be moderate,14,18–20 and both approaches allow for two-dimensional assessment of the macula only, so volumetric measurement of drusen and quantitative measurement of disease progression is impossible. Quantitative assessment of drusen, however, might become an important parameter in clinical trials to evaluate efficacy of new drugs against AMD.21,22 Here, spectral domain optical coherence tomography (SD-OCT) imaging offers several advantages: the same scan pattern can be used to obtain image data on both drusen and atrophic lesions of GA; it allows for acquiring three-dimensional data providing more detailed information on disease-specific changes in retinal structures; and it permits volumetric measurement of drusen for quantitative assessment of drusen progression as well as determination of lesion size in GA.21–28 Bearelly et al. demonstrated that SD-OCT margins of GA can be easily identified on SD-OCT fundus images and that B-scans relative to these GA margins can be graded for quantifying photoreceptor losses, and lujan et al. reported that SD-OCT fundus images can be used to identify and measure areas of GA.25,26

However, manual grading of SD-OCT images is time-consuming and carries the risk of interobserver variability. Recently, a new SD-OCT software analysis tool has been developed, mainly based on two new algorithms, which allows the automated and quantitative assessment of changes in drusen size and volume as well as in changes of GA areas and should allow the monitoring patients with AMD. The software received the Conformité Européenne (CE) mark in November 2011 and the Food and Drug Administration has granted approval to Carl Zeiss Meditec (Dublin, California, US) for this new software analysis tool for Cirrus™ HD-OCT. Here we present the first feasibility study of this new analysis tool.

Source data from SD-OCT images obtained from three patients using the cirrus HD-OCT were re-evaluated with the new software analysis tool Advanced [retinal pigment epithelium] RPE analysis (Carl Zeiss Meditec). Advanced RPE analysis was performed on macula 512 x 128 scan data from visits of three patients featuring different characteristics of confirmed dAMD.

Advanced RPE Analysis Tool
The Advanced RPE analysis software analysis tool is part of the new cirrus 6.0 software and provides basically two new algorithms. One measures elevations in the RPE for identifying drusen, and one measures areas of sub-RPE illumination where the OCT beam is able to penetrate through to the choroid, indicating that the RPE is atrophic. Variance in measurements is reduced by identifying the foveal centre on the OCT fundus image using an automated fovea localisation algorithm and comparing measurements from regions within circles of 3 and 5 mm centred on the fovea. The algorithm to detect the fovea attempts to identify the reduction in tissue between the RPE and the inner limiting membrane that occurs at the fovea. In the presence of floaters or significant tissue disruption, this algorithm may fail. In these cases, the clinician may identify the fovea manually. All calculations are centred on the fovea as identified by either the algorithm or the clinician.

Retinal Pigment Epithelium Elevation Map
The RPE elevation map is used to automatically determine drusen area and volume. It is important to understand that RPE segmentation is used as the starting point for the drusen analysis. So strictly speaking this analysis detects elevations in the RPE. To identify elevations, a curve is fitted to the RPE segmentation that seeks to exclude deformations of the RPE and follow the curvature of the eye. The region between the RPE segmentation and the curve fit is designated as RPE elevation. To allow for some variability in fitting, only areas where the elevation exceeds 10 pixels (19.5 μm) are used for calculations of RPE elevation area and volume. The RPE elevation map is an en face image presented in a pseudo-colour map using a colour scale that highlights elevations above 20 μm. This map is presented as a transparent image overlaying the OCT fundus. Transparency is preset at 50 %, although it can be adjusted manually.

Sub-retinal Pigment Epithelium Slab
The sub-RPE slab is a 6 by 6 mm image that represents a sum of the OCT reflectivity values measured beneath the RPE. The sub-RPE slab tends to be brighter in areas where significant OCT light penetrates below the RPE and returns to be collected. The image tends to be dimmer in areas of the retina where the RPE is intact because the RPE is highly scattered and absorbing and tends to prevent light from penetrating and returning to be detected by the OCT device. When the RPE has atrophied, the penetration of light beneath the RPE is increased, and the subsequent bright area on the sub-RPE slab can be used to determine the area of GA. Geographic atrophy is visualised as a bright area on the image due to the increased penetration of light into the choroid where atrophy has occurred in the macula. This increased light penetration associated with GA arises from the absence of the RPE and choriocapillaris, which are the two layers of the eye that normally cause the incident light to scatter and prevent deeper transmission of light into the choroid. The brightness on the OCT fundus image results from the summation of this increased light penetration relative to the surrounding tissue which still contains the intact RPE and choriocapillaris. This effect is enhanced in the sub-RPE slab image. The OCT image volume beneath the level of the RPE is processed to create a two-dimensional en face projection image that shows bright spots where the atrophy of RPE allows light to penetrate into the choroid. Segmentation is then performed on this en face image to identify areas of high sub-RPE illumination.

Presentation of Analysis Results
Within the Advanced RPE analysis tool, there are two screens available for reviewing the results. The first screen shows both the sub-RPE illumination results (sub-RPE slab with segmented lesions shown as outlines) and the RPE elevation (RPE elevation map) separately as en face images along with the corresponding horizontal tomograms (B-scan). The second screen shows a map (RPE profile) that integrates both analyses (RPE elevation and sub-RPE illumination) visualising all detected disturbances in the RPE. Furthermore, the following calculated values are presented along with a calculation of current minus prior and percentage change:

  • area of RPE elevations (mm2) within 3 and 5 mm circle;
  • volume of RPE elevations (mm3) within 3 and 5 mm circle;
  • area of sub-RPE illumination in 5 mm circle; and
  • distance measurement (mm) from nearest sub-RPE illumination to fovea.

Case 1
Case 1 represents data of an 86-year-old female with confirmed dAMD with drusen and GA in both eyes. Both eyes had cataract surgery with implantation of a blue light filtering intraocular lens. There was no history of other eye operations apart from that. Best corrected visual acuity (BCVA) in the left eye was 0.5 (20/40). SD-OCT data of the left eye collected at first and last visit (July 2011/January 2012) are compared in this Advanced RPE analysis to monitor disease. First screen analysis displays RPE elevation map as an overlay on the fundus image. The map shows circles corresponding to 3 and 5 mm in diameter centred on the fovea. The pseudo-colour aids in identifying bumps and discontinuities in the RPE. legends at the lateral margins of the map show correlation of colour to the height of the elevations. Furthermore, the sub-RPE slab with overlaid segmentation of sub-RPE illumination within 5 mm circle centred on the fovea is presented. Data of the first visit are presented on the left side, data of the last visit are presented on the right side (see Figure 1).

The sub-RPE slab shows perifoveal regions of increased penetration of light through the RPE, consistent with GA. This increased penetration of light is seen in the corresponding B-scan as well (see Figure 1, B-scan). The red line indicating the distance from the fovea to the closest area with sub-RPE illumination is very short and almost not visible in this analysis as GA has almost but not yet reached the fovea (see Figure 1, sub-RPE slab, left side).

In the RPE elevation map, RPE elevations are seen, especially within the 5 mm circle. There are also elevations outside the measurement area, which is indicated by a warning message. The RPE elevations indicating drusen increase between the two visits (see Figure 1). Quantitative conclusions are presented in the calculation analysis in the second screen (see Figure 2).

Second screen analysis shows the ‘RPE profile’ which integrates RPE elevation map and sub-RPE illumination: the sub-RPE illumination is overlaid on the RPE elevation and shown as an outline. This slab shows the location of the fovea with a dot marking and a circle corresponding to 5 mm in diameter centred on the fovea. Furthermore, calculated values are presented in a table (see Figure 2). Calculated values show that from July 2011 until January 2012 the drusen area increased by 0.4 mm (23.5 % change) within the 5 mm circle, whereas drusen volume increased from 0.06–0.07 mm3. In addition, the atrophic area changed from 0.6–0.7 mm2, which is within the test/retest variability for these measurements and thus could be regarded as measurement noise rather than real change (see Figure 2). These results correlate well with our clinical observation.

Case 2
Case 2 represents data of a 79-year-old female with confirmed dAMD with drusen and GA in both eyes. Both eyes had cataract surgery with implantation of a non-blue light filtering intraocular lens. There was no history of other eye operations apart from that. Best corrected visual acuity of the left eye was 0.25 and BCVA of the right eye was 0.16. SD-OCT data from left and right eye collected at first visit (october 2011) are presented in a ‘Patient report’, which can be printed after Advanced RPE analysis and can be kept with the patient’s documents. The Patient report shows all relevant data including RPE elevation map (1), sub-RPE slab (2), RPE profile (3) and the calculation analysis (see Figure 3A and B).

Case 2 represents a typical case of dAMD in which atrophy of the RPE results in a bright lesion that can be seen as a bright area in the sub-RPE slab image. Figure 3a shows RPE analysis of the left eye, figure 3b shows RPE analysis of the right eye. Both show some elevations within the 3 mm circle, indicating drusen. The sub-RPE slabs of both eyes present a central region where the penetration of light to the choroid is very strong, indicating an area of GA covering the fovea. The red line usually indicating the distance from the fovea to the closest area with sub-RPE illumination is not visible in this analysis as GA covers the fovea already in both eyes. This correlates well with our clinical observations and the low BCVA of 0.25 (left eye) and 0.16 (right eye).

Case 3
Case 3 represents data of an 83-year-old male with confirmed dAMD with drusen and GA in both eyes. Both eyes have cataract with no history of eye operations. Best corrected visual acuity of the left eye was 0.16 and BCVA of the right eye was 0.6. SD-OCT data of both eyes collected at first visit (December 2012) are presented in a Patient report (see Figure 4A and B).

This is another typical case of dAMD in both eyes. In the left eye (see Figure 4A) there are few RPE elevations visible in the RPE elevation map. The sub-RPE slab shows a large central region where the penetration of light to the choroid is very strong, indicating that GA already covers the fovea. These results correlate well with our fundus examinations and the BCVA of 0.16 in the left eye. In the right eye there is a large perifoveal area with strong penetration of light into the choroid, indicating that the geographic area has not yet reached the fovea. Retinal pigment epithelium elevation map shows that there are some elevations within the 5 mm circle, indicating drusen. This correlates well with our fundus examination and a BCVA of 0.6 in the right eye.

This first feasibility study including case reports of three patients representing different features of dry AMD shows that with the newly developed Advanced RPE analysis software analysis tool the status of the RPE can be objectively and automatically examined in detail and can be followed over time. Drusen area and volume as well as area of GA can be measured and analysis results are presented along with calculated values in two clearly arranged screens. An automated fovea localisation algorithm assures that measurements from regions within circles of 3 and 5 mm centred on the fovea are compared, and as data of prior and current visit are placed side by side, changes between visits are easily detectable and can be followed over time. Another major advantage of SD-OCT imaging lies in using only one type of scan for documenting both en face and cross-sectional images of the retina. It therefore provides more detailed insight in retinal alterations of GA patients than FAF, which has already been described.25–27 As on the first screen analysis, the fundus image is presented along with the corresponding B-scans, which offers the opportunity to comfortably gather detailed information about the retinal structural changes in these areas (see Figure 1). This contributes to better understanding of the relationship between GA enlargement, loss of photoreceptor/RPE and visual loss, and thus could help to expand the knowledge of disease-specific retinal alterations and disease progression.

Efficacy and reproducibility of both new algorithms for identifying RPE-elevation and sub-RPE illumination underlying this new tool have been shown already. Yehoshua et al. evaluated in a prospective study with 81 eyes the area and enlargement rate of atrophic lesions with a mean follow-up time of 1, 24 years. They demonstrated high reproducibility of this algorithm and concluded that SD-OCT fundus images can be used to visualise and quantify GA and that precision is sufficient to reliably measure lesions as small as 0.12 mm2 (0.05 DA).28 Gregori et al. quantitatively assessed drusen volume and area in 103 eyes from 74 patients with drusen and concluded that the new algorithm was highly reproducible for qualitative and quantitative assessment of drusen.22

Using the Advanced RPE analysis tool, we were able to automatically measure areas of GA as well as drusen area and volume in three patients with confirmed dAMD. Results from the RPE analysis were in agreement with our clinical observations in all cases. Although we here present only three cases of dAMD within this first feasibility study, it seems reasonable to say that the new software provides for the first time the possibility for automatically quantitative and volumetric assessment of drusen. As drusen are a meaningful parameter of AMD, this tool may help to better evaluate disease progression. However, it has to be kept in mind, that very shallow drusen <20 μm are not detectable with this new tool. In this regard gregori et al. already pointed out that SD-OCT and fundus photography deliver different information: whereas SD-OCT images indicate RPE disruption, fundus photographs show pigmentary changes. So, due to threshold limitations very shallow drusen may be missed in advanced RPE analysis whereas not all RPE deformations must be associated with pigmentary changes and thus will not appear on fundus photographs. Therefore, both methods offer complementary information and may thus have an important role in assessing drusen in patients with AMD.22

So far, a limitation of the new analysis tool might be that only lesions fitting within the 5 mm circle centred around the fovea can be measured and evaluated. However, this might be resolved with new algorithms that are capable of assembling multiple overlapping SD-OCT images, so that any area can be measured.

Today, SD-OCT allows for high-speed, high-resolution imaging of retinal structures and provides non-invasive three-dimensional information on retinal pathology in situ and in real time. It thus leads to a more profound understanding of a patient’s RPE status, which is a relevant structure in all forms of AMD. Within the new Advanced RPE analysis software, SD-OCT technology is combined with robust algorithms that allow for automated, quantitative assessment of drusen and atrophic lesions, and could allow for more objective and easier classification of AMD. As drusen and atrophic lesions can be evaluated from the same scan pattern, all forms of AMD can be assessed quantitatively. Furthermore it allows for the detection of morphologic alterations over time, which should – in conjunction with functional testing – aid in the stratification of stages of disease progression. This would be useful for monitoring progression of disease over time and provides the opportunity to monitor the effectiveness of new therapies in clinical trials. Of course, in this context it is of utmost importance to define and evaluate reliable and reproducible parameters for grading AMD using SD-OCT. As the new software tool allows for objective and automated measurements, large patient populations can be monitored easily. In this respect it is also advantageous that SD-OCT images based on former cirrus HD-OCT software can be re-evaluated with the new analysis tool. Furthermore, it has already been described that the junctional zone of GA is the site of disease activity and will be the target for effective therapeutic strategies against dAMD.23 Here, the new analysis tool could prove useful as it provides simultaneous measurement of GA along with three-dimensional visualisation of the RPE and thus can comfortably be used to gain new insight in microstructural changes underlying disease progression. Our results with this new analysis tool are promising, although further studies evaluating reproducibility, efficacy and feasibility of this new RPE analysis tool are required.

Article Information:

The author has no conflicts of interest to declare.


Albert J Augustin, Staedtisches Klinikum Karlsruhe, Augenklinik, Moltkestrasse 90, 76133 Karlsruhe, Germany. e: albertjaugustin@googlemail.com


The publication of this article was funded by Carl Zeiss Meditec.




  1. Resnikoff S, Pascolini D, Etya’ale D, et al., Global data on visual impairment in the year 2002, Bull World Health Organ, 2004;82:844–51.
  2. Klein R, Klein BE, Lee KE, et al., Changes in visual acuity in a population over a 15-year period: the Beaver Dam eye study, Am J Ophthalmol, 2006;142:532–49.
  3. Gehrs KM, Anderson DH, Johnson lV, Hageman GS, Age related macular degeneration –emerging pathogenetic and therapeutic concepts, Ann Med, 2006;38:450–71.
  4. Klein R, Chou CF, Klein BE, et al., Prevalence of age-related macular degeneration in the US population, Arch Ophthalmol, 2011;129:75–80.
  5. Friedman DS, O’colmain BJ, Muñoz B, et al., Eye Diseases Prevalence research group. Prevalence of age-related macular degeneration in the united states, Arch Ophthalmol, 2004;122:564–72.
  6. Age-related Eye Disease Study Research Group, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8, Arch Ophthalmol, 2001; 119:1417–36.
  7. Augustin AJ, Schmidt-Erfurth U, Kritische worte zur ARED studie, Ophthalmologe, 2002; 99:299–300.
  8. Heidrich H, Harnisch JP, Ranft J, PGE1 bei seniler maculadegeneration. Pilot-studie, Klin Monatsbl Augenheilkd, 1989;194:282–4.
  9. ladewig MS, ladewig K, Güner M, Heidrich H, Prostaglandin E1 infusion therapy in dry age-related macular degeneration, Prostaglandins leukot essent fatty Acids, 2005;72:251–6.
  10. Multicenter investigation of rheopheresis for AMD (MIRA-1) study group, Pulido JS, Multicenter prospective, randomized,double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis, Trans Am Ophthalmol Soc, 2002;100:85–108.
  11. Zarbin MA, Rosenfeld PJ, Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives, Retina, 2010;30:1350–67.
  12. Klein R, Klein BE, Tomany SC, et al., Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study, Ophthalmology, 2002;109:1767–79.
  13. Klein R, Davis MD, Magli Yl, et al., The Wisconsin Age-related Maculopathy grading system, Ophthalmology, 1991; 98:1128–34.
  14. Davis MD, Gangnon RE, lee lY, et al., Age-related eye Disease study research group, The Age-related eye Disease study severity scale for age-related macular degeneration: AREDS report no. 17, Arch Ophthalmol, 2005;123:1484 –98.
  15. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al., Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration, Am J Ophthalmol, 2007; 143:463–72.
  16. Holz FG, Bellman C, Staudt S, et al., Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration, Invest Ophthalmol Vis Sci, 2001; 42:1051–6.
  17. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al., Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD, Invest Ophthalmol Vis Sci, 2006;47:2648 –54.
  18. Sunness JS, Ziegler MD, Applegate CA, Issues in quantifying atrophic macular disease using retinal autofluorescence, Retina, 2006; 26:666–72.
  19. Scholl HP, Peto T, Dandekar S, et al., Inter- and intraobserver variability in grading lesions of age-related maculopathy and macular degeneration, Graefes Arch Clin Exp Ophthalmol, 2003; 241:39–47.
  20. Pirbhai A, Sheidow T, Hooper P, Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration, Am J Ophthalmol, 2005; 139:455–61.
  21. Yehoshua Z, Rosenfeld PJ, Gregori G, Penha F, Spectral domain optical coherence tomography imaging of dry agerelated macular degeneration, Ophthalmic Surg Lasers Imaging, 2010;41:s6–14.
  22. Gregori G, Wang F, Rosenfeld PJ, et al., Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration, Ophthalmology, 2011;118:1373–9.
  23. Sayegh RG, Simader C, Scheschy U, et al., A systematic comparison of spectral domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy, Ophthalmology, 2011;118:1844–51.
  24. Yehoshua Z, Rosenfeld PJ, Gregori G, et al., Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography, Ophthalmology, 2011;118:2434–41.
  25. Bearelly S, Chau F, Koreishi A, et al., Spectral domain optical coherence tomography imaging of geographic atrophy, Ophthalmology, 2009;116:1762–9.
  26. lujan BJ, Rosenfeld PJ, Gregori G, et al., Spectral domain optical coherence tomographic imaging of geographic atrophy, Ophthalmic Surg Lasers Imaging, 2009;40:96–101.
  27. Brar M, Kozak I, Cheng l, et al., Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy, Am J Ophthalmol, 2009;148:439–44.
  28. Yehoshua Z, Rosenfeld PJ, Gregori G, et al., Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography, Ophthalmology, 2011;118:679–86.

Further Resources

Share this Article
Related Content In Imaging
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72